Investor Overview

Corporate Profile

Protagonist Therapeutics is a clinical stage biopharmaceutical company that utilizes a proprietary technology platform to discover and develop novel peptide-based drugs to transform existing treatment paradigms for patients with significant unmet medical needs. PTG-100 is an oral alpha-4-beta-7 integrin antagonist peptide  that was being developed for inflammatory bowel diseases (IBD). ... Read more

Stock Quote

PTGX (Common Stock)
$8.75 - 0.17 (1.91%)
Exchange :NASDAQ
Volume :132,516
Today's Open$8.91
Previous Close$8.92
Data as of April 19, 2018 4:00 p.m. ET
Refresh quote

Stock Chart

Stock chart for: PTGX.O.  Currently trading at $8.75 with a 52 week high of $23.97 and a 52 week low of $7.85.

Recent Press Releases

March 26, 2018

Protagonist Therapeutics Discontinues Phase 2b PROPEL Trial of PTG-100 for the Treatment of Ulcerative Colitis following Interim Analysis read more

March 09, 2018

Protagonist Therapeutics to Participate in the 28th Annual Oppenheimer Healthcare Conference read more

March 07, 2018

Protagonist Therapeutics Reports Fourth Quarter and Year-End 2017 Financial Results read more

Upcoming Events

There are currently no events scheduled.


Data provided by Nasdaq. Minimum 15 minutes delayed.